Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

Abivax starts second phase IIa trial of ABX464 in HIV/AIDS patients By PBR Staff Writer
Abivax has enrolled first patient in second phase IIa trial of ABX464 drug candidate in HIV/AIDS patients.
Contract Research & Services > Clinical Trials > News
AstraZeneca’s Faslodex meets primary endpoint in breast cancer trial By PBR Staff Writer
AstraZeneca’s Faslodex has met primary endpoint in first-line treatment of advanced breast cancer in the phase III Falcon trial.
Contract Research & Services > Clinical Trials > News Symbiomix reports positive results for SYM-1219 in bacterial vaginosis By PBR Staff Writer
Symbiomix Therapeutics' SYM-1219 (secnidazole) has achieved statistically and clinically significant results across all primary and secondary endpoints in phase 3 trial for bacterial vaginosis (BV).
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
Roche’s phase III study of Gazyva meets primary endpoint early
By PBR Staff Writer
Roche's Gazyva drug demonstrated superior progression-free survival compared to Mabthera/Rituxan in people with previously untreated follicular lymphoma in the phase III Gallium study that met its primary endpoint early.
Contract Research & Services > Clinical Trials > News
AVEO Oncology doses first patient in phase 3 TIVO-3 study of tivozanib in renal cell carcinoma
AVEO Oncology has dosed the first patient in its pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
Contract Research & Services > Clinical Trials > News
Seattle Genetics starts phase 3 trial of vadastuximab talirine for newly diagnosed AML patients
By PBR Staff Writer
Seattle Genetics has started a phase 3 trial of vdastuximab talirine (SGN-CD33A) for patients with newly diagnosed acute myeloid leukemia (AML).
Contract Research & Services > Clinical Trials > News
Alkermes starts phase 1 trial of immuno-oncology drug candidate ALKS 4230
By PBR Staff Writer
Biopharmaceutical firm Alkermes has started a phase 1 clinical study of its immuno-oncology drug candidate, ALKS 4230.
Contract Research & Services > Clinical Trials > News
GSK's Relvar Ellipta succeeds in Salford lung study
A ground-breaking study has demonstrated that GlaxoSmithKline's (GSK) Relvar Ellipta is better than the usual care in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Contract Research & Services > Clinical Trials > News
Cellceutix's phase 2 trial of Prurisol to treat mild to moderate psoriasis meets primary endpoint
By PBR Staff Writer
The phase 2 trial of Cellceutix's Prurisol to treat mild to moderate chronic plaque psoriasis has met its primary endpoint.
Contract Research & Services > Clinical Trials > News
Isofol announces successful meetings with European and US regulatory authorities on design of phase II trial of Modufolin
Isofol Medical has announced successful meetings with European and US regulatory authorities regarding the design of a pivotal Phase II clinical trial of Isofol’s lead Drug candidate, Modufolin.
Contract Research & Services > Clinical Trials > News
Exelixis unveils positive results from phase 2 trial of cabozantinib in previously untreated advanced RCC
Exelixis has unveiled positive top-line results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC).
Contract Research & Services > Clinical Trials > News
Vtesse completes dose-finding part of phase 2b/3 trial for VTS-270 to treat Niemann-Pick Type C1 disease
Vtesse has announced that the dose-finding portion of the company’s global, pivotal Phase 2b/3 clinical trial for its lead investigational product, VTS-270, for treatment of Niemann-Pick Type C1 Disease (NPC) is now complete, and a dose level for further testing has been selected by an independent dose selection committee (DSC).
Contract Research & Services > Clinical Trials > News
CoLucid Pharmaceuticals starts second phase 3 trial of lasmiditan in migraine
CoLucid Pharmaceuticals has randomized the first patient in its SPARTAN study, the Company’s second Phase 3 pivotal trial of lasmiditan.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests